1.Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy
Fares Mohammed SAEED MUTHANNA ; Mahmathi KARUPPANNAN ; Bassam Abdul RASOOL HASSAN ; Ali Haider MOHAMMED
Osong Public Health and Research Perspectives 2021;12(2):115-125
Objectives:
Fatigue is the most frequently reported symptom experienced by cancer patients and has a profound effect on their quality of life (QOL). The study aimed to determine the impact of fatigue on QOL among breast cancer patients receiving chemotherapy and to identify the risk factors associated with severe fatigue incidence.
Methods:
This was an observational prospective study carried out at multiple centers. In total, 172 breast cancer patients were included. The Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire was used to measure QOL, while the Brief Fatigue Inventory (BFI) was used to assess the severity of fatigue.
Results:
The total average mean and standard deviation of QOL were 84.58±18.07 and 4.65±1.14 for BFI scores, respectively. A significant association between fatigue and QOL was found in linear and multiple regression analyses. The relationships between fatigue severity and cancer stage, chemotherapy dose delay, dose reduction, chemotherapy regimen, and ethnicity were determined using binary logistic regression analysis.
Conclusion
The findings of this study are believed to be useful for helping oncologists effectively evaluate, monitor, and treat fatigue related to QOL changes.
2.Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy
Fares Mohammed SAEED MUTHANNA ; Mahmathi KARUPPANNAN ; Bassam Abdul RASOOL HASSAN ; Ali Haider MOHAMMED
Osong Public Health and Research Perspectives 2021;12(2):115-125
Objectives:
Fatigue is the most frequently reported symptom experienced by cancer patients and has a profound effect on their quality of life (QOL). The study aimed to determine the impact of fatigue on QOL among breast cancer patients receiving chemotherapy and to identify the risk factors associated with severe fatigue incidence.
Methods:
This was an observational prospective study carried out at multiple centers. In total, 172 breast cancer patients were included. The Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire was used to measure QOL, while the Brief Fatigue Inventory (BFI) was used to assess the severity of fatigue.
Results:
The total average mean and standard deviation of QOL were 84.58±18.07 and 4.65±1.14 for BFI scores, respectively. A significant association between fatigue and QOL was found in linear and multiple regression analyses. The relationships between fatigue severity and cancer stage, chemotherapy dose delay, dose reduction, chemotherapy regimen, and ethnicity were determined using binary logistic regression analysis.
Conclusion
The findings of this study are believed to be useful for helping oncologists effectively evaluate, monitor, and treat fatigue related to QOL changes.
3.Hepatitis B x protein activated vascular endothelial growth factor expression through hypoxia inducible factor-1 pathway.
Hai-ping WANG ; Xiao-ping CHEN ; Lei DING ; Song-qing HE ; Muthanna ALI ; Dong-hua LI ; Wan-guang ZHANG
Chinese Journal of Oncology 2003;25(5):433-436
OBJECTIVETo investigate whether hepatitis B x protein (HBx) stimulates vascular endothelial growth factor (VEGF) through hypoxia inducible factor-1 (HIF-1 alpha) pathway.
METHODSTwo plasmids including pIRES-EGFP-HBx and pTK-Hyg were co-transfected to a hepatocellular carcinoma cell line SMMC-7721. With fluorescence-positive and fluorescence-negative hygromycin-resistant colonies selected, expressions of VEGF and HIF-1 alpha in protein or/and mRNA level were detected.
RESULTSFluorescence-positive cells were stably integrated with HBx, in which expression of HIF-1 alpha and VEGF were upregulated. Fluorescence-negative cells did not express HBx, VEGF or HIF-1 alpha.
CONCLUSIONHBx can activate VEGF through HIF-1 alpha pathway.
Cell Line, Tumor ; Gene Expression Regulation ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit ; Trans-Activators ; physiology ; Transcription Factors ; genetics ; physiology ; Vascular Endothelial Growth Factor A ; genetics ; physiology